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Introduction. This pilot study evaluated the expression of the proinflammatory cytokine IL-17 along the Barrett’s metaplasia-
dysplasia-adenocarcinoma sequence by establishing the expression levels of IL-17 in columnar epithelium, intestinal metaplastic
cells, and dysplastic/glandular neoplastic cells. Immunohistochemical techniques were used to examine the accumulation of
the proinflammatory cytokine IL-17 in forty (n = 40) formalin-fixed, paraﬃn-embedded oesophageal archived specimens
across a range of endoscopic diagnostic categories, and a highly significant diﬀerence was found, where P ≤ 0.001, in IL-
17 expression (Kruskall Wallis and Mann-Whitney U) between all the cell types examined. There was also a strong positive
correlation (Spearman’s rank correlation) between disease progression and IL-17 expression (rs = 0.883, P < 0.001, n = 29), IL-17
expression was absent or absent/weak in columnar epithelium, weak to moderate in columnar metaplastic cells, and moderate
to strong in dysplastic/neoplastic cells, which demonstrated that the elevation of IL-17 expression occurs in the progression of
the disease. Understanding the diﬀerential expression of IL-17 between benign and malignant tissue potentially has a significant
diagnostic, prognostic, and therapeutic value. Ultimately, this selective biomarker may be employed in routine clinical practice for
the screening of oesophageal adenocarcinoma.
1. Introduction
Oesophageal Adenocarcinoma (OAC) is the focus of intense
research into the cause of the disease and treatment [1].
In the context of OAC screening, a biomarker capable of
reliably predicting progression to dysplasia or cancer by
increased expression is highly valuable [2]. Oesophageal
cancer develops symptoms late in the course of this disease
and carries a poor prognosis. In the UK, oesophageal cancer
is the eleventh most commonly diagnosed cancer and, of
greater concern, the sixth most common cause of death
from cancer, which represented 1 : 20 of all cancer deaths in
the UK; 8,161 new cases were diagnosed in 2009 and the
mortality rate was 7,610 in 2010 [3].
The role of inflammation in the development of OAC
is not well understood, unlike its role in colon and breast
cancers. However, this role in the progression of OAC is
now beginning to gain greater attention [4]. Proinflam-
matory cytokines and their pathways are associated with
inflammation in Barrett’s oesophagus and tumourigenesis.
Elucidating the association between inflammation and OAC
may contribute to the eventual prevention of OAC [5].
Further assessment of these cytokines has recently been
recommended, as these may be important targets for early
diagnosis and chemoprevention drugs [6, 7].
Inflammatory factors are commonly associated with
contributing to the development of tumours; chronic inflam-
mation is often associated with malignancy [8]. Abdel-
Latif et al. [5] concluded that chronic inflammation plays
a crucial role in the pathogenesis of the disease where
inflammatory cytokines are linked with advancement of
tumourigenesis. IL-17 induces a wide variety of factors,
which include chemokines, cytokines, acute phase proteins,
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tissue remodelling proteins, antimicrobial proteins, and
nitric oxide. Cytokines that induce IL-17 include IL-6
and IL-8, and expression increases in both as the disease
progresses. β-defensin, indirectly induced by IL-17, recruits
dendritic cells and T lymphocytes to the inflamed site in the
oesophagus through interaction with chemokine receptor
(CCR) 6. Chemokine (C-C motif) ligand (CCL) 20 is up-
regulated by IL-17, a chemokine that also attracts dendritic
cells and T lymphocytes to the inflamed site. β-defensins and
CCL20 serve to recruit and extend the TH17 population at
the inflamed site [9]. IL-17 is implicated in several chronic
inflammatory diseases, including the autoimmune diseases,
rheumatoid arthritis (RA), and psoriasis [10, 11].
Recent evidence suggests that the presence of infiltrating
IL-17+ cells, which include lymphocytes, mast cells, and
neutrophils, in patients with OAC, may have a pathogenic
role in this disease. Several studies have demonstrated a high
frequency of IL-17+ cells in inflammation-related cancers
including OAC [12], nonsmall cell lung carcinoma, where
IL-17 has been implicated in metastasis of lung cancer by
promoting lymphangiogenesis [13] and hepatocellular car-
cinoma where IL-17 is also believed to promote angiogenesis
[14].
The aim of this pilot study was to evaluate the expression
of the proinflammatory cytokine IL-17 along the Barrett’s
metaplasia-dysplasia-carcinoma sequence by establishing the
expression levels of IL-17 in columnar epithelium, intestinal
metaplastic cells, and dysplastic/glandular neoplastic cells.
2. Materials andMethods
Ethics Statement. This study, which included the use of
archived human tissue samples, was approved in writ-
ing by the Proportionate Review Sub-Committee of the
National Research Ethics Service Committee East Midlands-
Nottingham 2 Research Ethics Committee in the United
Kingdom, reference 11/EM/0384, on November 23 2011.
Written permission for this study was also received from the
Research and Development Directorate at Aintree University
Hospital National Health Service Foundation Trust, refer-
ence 451/11, on November 28 2011.
Forty distal oesophageal biopsy samples embedded in
formalin-fixed paraﬃn blocks, originally collected between
2010 and 2011, were retrieved from the Cellular Pathology
department archive at Aintree University Hospitals National
Health Service Foundation Trust, UK; ten from each of the
following endoscopic examination result categories: Normal
oesophagus, reflux oesophagitis, Barrett’s oesophagus, and
oesophageal adenocarcinoma. The mean age of the patients
involved with this study was 71 years (range: 49–88).
The IL-17 expression in columnar epithelium, columnar
metaplastic cells, and dysplastic/glandular neoplastic cells
was compared. A negative control was established using
an internal control on each slide (squamous mucosa), and
a positive control was established, which was taken from
normal kidney tissue. Immunohistochemistry was with IL-
17 antibody, and counter stained with haematoxylin.
The rabbit polyclonal antibodies against human origin
IL-17 sc7927 from Santa Cruz Biotechnology (SCBT) have
been used extensively in recent studies, including human
immunohistochemical studies; therefore, this IL-17 antibody
was selected for use by this study. The dilutions 1 : 50,
1 : 100, and 1 : 200 of the IL-17 antibody were prepared
as recommended by SCBT, and the stained tissue sections
were examined via microscopy to find the initial optimum
dilution, which was 1 : 50. Further dilutions were prepared,
which included 1 : 30, 1 : 40, 1 : 50, and 1 : 60, and of these, the
1 : 40 dilution was the optimum to visualise IL-17 expression
in the patient tissue samples. The same batch of this primary
antibody was used throughout. Sample sections were cut at
2 μm. All positive controls were taken from a human kidney
biopsy [15].
Prior to staining, the antigens were unmasked at 97◦C
with a target retrieval solution at pH 9.4. 30mL of Dako
EnVision FLEX Target Retrieval Solution (High pH 50x) was
added to 1.5 L of distilled water and treated at 97◦C for 20
minutes using the Dako PT link machine (Dako).
The primary IL-17 antibody (1 : 40 dilution in Dako
REAL Antibody Diluent, Santa Cruz Biotechnology, USA)
was used in this study. Staining was conducted using Dako
Autostainer Link 48 (Dako), which added 300 μL of undi-
luted Dako EnVision FLEX Peroxidase-Blocking Reagent to
each slide for 5 minutes. 300 μL of diluted IL-17 antibody
was subsequently added to each slide for 30 minutes. The
treatment continued by adding 300 μL of undiluted Dako
EnVision FLEX+ Rabbit (Linker) to each slide for a further
15 minutes. After the Linker treatment, 300 μL of undiluted
Dako EnVision FLEX/horseradish peroxidase (HRP) was
added to the slides for 20 minutes. This was followed by
adding a 300 μL of diluted chromogen reagent to each slide
for 5 minutes, followed by a buﬀer wash, and then by a
second application of 300 μL of diluted chromogen for 5
minutes. The diluted chromogen was prepared by placing 20
drops of Dako EnVision FLEXDAB+Chromogen into 20mL
of Dako EnVision FLEX Substrate Buﬀer. The final step
of the automated autostainer process was to add 300 μL of
Dako EnVision FLEX Haematoxylin (Link) to each slide for
5 minutes. Between each treatment, the slides were washed
with a diluted wash buﬀer. The diluted wash buﬀer consisted
of 0.5 L Dako EnVision FLEX Wash Buﬀer (20x) and 10 L of
distilled water. This buﬀer was placed into a large container
that was connected to the Autostainer.
Before the cover slips were mounted, the sections were
dehydrated by the Leica ST4040 system (Leica). The sections
were dehydrated in ascending alcohols (50%, 70%, and 99%
twice) for 15 seconds each using Alcohol Methylated Spirit
99% (GentaMedical) diluted with distilled water. The system
treated the slides with Xylene (Genta Medical) for 5 minutes.
After the section dehydration, the slides were placed into the
automated cover slipper, the Leica CV5000 (Leica).
3. Histological Evaluation of IL-17 Staining
Two experienced pathology laboratory staﬀ independently
assessed tissue sections for the staining intensity of IL-17,
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with scoring from 0 to 3 (0—no staining, 1—week intensity,
2—medium intensity, and 3—high intensity).
The One-way nonparametric ANOVA (Kruskal-Wallis
test), and the Mann-Whitney U test were used to determine
if there was a diﬀerence in IL-17 expression. Pairwise
comparisons were made between the columnar epithelium,
intestinal metaplastic cells, and dysplastic cells/glandular
neoplastic cells. The association between disease progression
and the level of expression of IL-17 was evaluated using
Spearman’s rank correlation method to determine whether
there was an association between disease progression and
the expression of IL-17. The original Haematoxylin and
Eosin (H&E) slides were used to compare the morphological
features of the samples with the IL-17 staining.
4. Results
Expression levels of IL-17 in columnar epithelium, intesti-
nal metaplasia, and dysplasia/glandular neoplasia were
compared. There was significant diﬀerence between the
expression of IL-17 between the three diﬀerent cell types
(columnar epithelium, intestinal metaplastic cells, and dys-
plastic/glandular neoplastic cells), (X2 = 21.852, df =
2, P < 0.001, n = 29, Figure 1). Squamous epithelium
included in the paraﬃn-embedded blocks demonstrated
absent cytoplasmic staining and acted as an internal neg-
ative control (Figure 2). Kidney-tissue positive controls
demonstrated strong IL-17 expression with the collecting
ducts (Figure 2). At the optimal concentration, columnar
epithelium demonstrated absent IL-17 staining in 3 of 7
(43%) or absent/weak staining (Figure 2) in 4 of 7 (57%).
Interestingly, the staining was distributed throughout the
cytoplasm, and the stains were uniform for all the cell types
examined (n = 29). For the 11 intestinal metaplasia samples,
5 of 11 (46%) demonstrated moderate staining (Figure 2), 4
of 11 (36%) demonstrated weak staining, and 2 of 11 (18%)
demonstrated absent/weak staining. These staining scores
were elevated when compared with columnar epithelium,
as demonstrated by the staining intensity scores, and the
diﬀerence was highly significant diﬀerence (MWU, Z =
−3.242, P = 0.001, n = 18). For the 11 dysplasia and
glandular neoplasia regions, 6 of 11 (55%) demonstrated
strong staining (Figure 2), 4 of 11 (36%) demonstrated
moderate staining, and 1 of 11 (9%) demonstrated moder-
ate/strong staining. These staining scores were elevated when
compared with columnar epithelium, and also with intestinal
metaplasia; these were (MWU, Z = −3.598, P < 0.001,
n = 18) and (MWU, Z = −3.483, P < 0.001, n = 22),
respectively. Neutrophils (n = 6) and mast cells (n = 7)
found in normal, Barrett’s oesophagus, and OAC cases were
all strongly positive. Surprisingly, only one case of plasma
cells (n = 1) was found in an oesophagitis case, and it was
strongly positive.
The Spearman rank correlation coeﬃcient (non-
parametric correlation analysis method) revealed that there
was a highly significant correlation (rs = 0.883, P < 0.001,
n = 29) between IL-17 expression and the progression
of the disease, where the disease progresses stepwise from
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Figure 1: Boxplot of the IL-17 staining intensity scores. Demonstra-
tion of the median (bold horizontal line), interquartile range (box
where given) and whiskers to highest and lowest levels. Negative
controls (n = 16), positive control (n = 8)—note: 1 positive control
per batch run, columnar epithelium (n = 7), intestinal metaplastic
cells (n = 11), dysplastic/glandular neoplastic cells (n = 11),
neutrophils (n = 6), mast cells (n = 7), plasma cells (n = 1).
columnar epithelium to intestinal metaplasia, and onwards
towards dysplasia and glandular neoplasia. There was a
strong positive correlation between disease progression and
IL-17 expression, and this suggests that IL-17 expression
increases as the disease progresses.
Immunohistochemistry staining scores were validated by
comparing the scores between two independent observa-
tions. The Cohen’s Kappa test results indicated that there was
“almost perfect agreement” (k = 1.00, n = 29) between
the intensity scores provided by Dr. Abdul Khan and Mr.
David Eccleston, both experienced histology pathology staﬀ
at the Aintree University Trust Hospital. Their long working
relationship together within the Trust may have led to the
high scoring concordance.
5. Discussion and Conclusion
The findings, that there is a highly significant increase in IL-
17 expression between columnar epithelium and intestinal
metaplastic cells, and between intestinal metaplastic cells and
dysplastic/glandular neoplastic cells in the distal oesopha-
gus, are novel (Figure 1). Amongst the native squamous
oesophagus and oesophageal columnar epithelium, there
was little or no expression of IL-17. The trigger for IL-17
elevated expression is not clear. There appears to be a stage
in the transition between columnar epithelium to intestinal
columnar epithelium where expression of IL-17 becomes
apparent. During the investigation some IL-17 staining of
the nuclei, but not cytoplasm, was observed in the columnar
epithelium and squamous mucosa; this may be an indication
of the transition phase where IL-17 becomes apparent.
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(a) (b) (c)
(d) (e)
Figure 2: Expression of interleukin-17. (a) is an IL-17 positive control (human kidney). The epithelium lining the kidney collecting ducts
was strongly stained. Magnification×100. (b) is an IL-17 negative control and demonstrates IL-17 immunohistochemistry treatment within
the oesophageal squamous mucosa. IL-17 staining is brown when present. Magnification ×200. (c) demonstrates IL-17 expression in the
columnar epithelium (without intestinal metaplasia) where IL-17 staining was absent/weak. Magnification ×200. (d) demonstrates IL-17
expression in the intestinal metaplasia where the IL-17 stain intensity was moderate. Intestinal metaplastic cells surround the goblet cells.
Magnification×100. (e) demonstrates IL-17 expression in the glandular neoplastic cells where IL-17 stain intensity was strong. IL-17 staining
was absent within the neighbouring squamous mucosa region. Magnification ×200.
TH17 cells secrete IL-17. TH17 cells are associated with
mucosal immunity, particularly within the gastrointestinal
tract, and autoimmune diseases. A study examining gastric
cancer conducted by Zhang et al. [15] found IL-17 mRNA
expression in the majority of the tumour samples, and
expression was not detected in the patient’s normal gastric
tissue. This concurs with the finding of this study in that
IL-17 expression is elevated in tissue aﬀected by OAC at a
level significantly greater level than that found in normal
tissues. Radosavljevic et al. [16] studied serum IL-17 levels
in patients with colorectal carcinoma and found significantly
higher IL-17 serum levels in patients with colorectal carci-
noma than found in healthy subjects. Their study indicated
that IL-17, combined with other serummarkers, is a valuable
tumour marker in patients with colorectal carcinoma, which
may provide additional information about the characteristics
of the tumour. Examining similar serum markers against
a possible case of Barrett’s oesophagus or oesophageal
adenocarcinoma may also provide valuable diagnostic and
prognostic information, which oﬀers the prospect of an
alternative cost-eﬀective and noninvasive approach to the
clinician.
Recent research suggests that there is a diverse range
of IL-17 producing cells amongst the immune system
community, and innate immunity cells may secrete IL-
17 [17]. Mast cells and neutrophils were found in nor-
mal, Barrett’s oesophagus, and OAC cases. Mast cells and
neutrophils were associated with strong IL-17 expression
in this study, suggesting that these innate immune cells
have an active role in maintaining high levels of IL-17
amongst the disease-aﬀected tissues. Lin et al. [18] studied
the pathogenesis of psoriasis and demonstrated that mast
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cells and neutrophils, rather than T lymphocytes, are the
prominent immune cell types that express IL-17 in the
human skin. Release of IL-17 frommast cells and neutrophils
may be important to the pathogenesis of OAC and may
have a similar pattern of chronic inflammation as seen in
psoriasis.
Clear evidence of any lymphocyte involvement in the
normal, Barrett’s oesophagus, or OAC cases was not found.
However, the stroma was aﬀected by strong background
staining, and it was diﬃcult to diﬀerentiate between stroma
and inflammatory cells via microscopy. Diﬃculties were
also experienced in attempting to make this distinction in
the corresponding archived haematoxylin and eosin stained
slides; there was significant background staining in most
of these cases, and because of these problems, the stroma
regions found in the cases examined were not included in
the results. Reducing the concentration of the IL-17 antibody
may have aided interpretation within the stroma, but at the
expense of being able to interpret regions outside the stroma;
these regions (outside the stroma) would deviate from their
optimum concentration.
This study demonstrated that IL-17 expression increases
as the disease progresses along the metaplasia-dysplasia-
carcinoma sequence, which potentially has a significant
diagnostic, prognostic, and therapeutic value. Understand-
ing the diﬀerential expression of IL-17 between benign
and malignant tissue may allow diagnostic, prognostic,
and therapeutic strategies to be developed. The evidence
presented by this study suggests that IL-17 has a role in the
development of OAC, which merits further investigation.
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